JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal2 days ago

    [$$] Pain Treatment Developer Centrexion Reveals IPO Plans

    Centrexion Therapeutics Corp., a pain treatment developer founded by the former leaders of Pfizer Inc. and Celgene Corp., on Friday disclosed plans to go public.

  • An Overview of JNJ’s Women’s Health & Wound Care Businesses
    Market Realist2 days ago

    An Overview of JNJ’s Women’s Health & Wound Care Businesses

    Johnson & Johnson’s (JNJ) women’s health business generated revenue of $269.0 million in the third quarter compared to $270.0 million in the third quarter of 2017. In the US and international markets in the quarter, the business generated revenues of $3.0 million and $266.0 million, respectively.

  • A Performance Overview of JNJ’s Beauty and OTC Businesses
    Market Realist2 days ago

    A Performance Overview of JNJ’s Beauty and OTC Businesses

    Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.

  • Investopedia2 days ago

    2 Dow Safety Stock for Volatile Market: Portfolio Manager

    As the Dow Jones Industrial Average (DJIA) index experiences a period of heightened volatility, healthcare stocks have proved relatively immune to the wider market swings. Healthcare players Pfizer Inc. ( PFE), UnitedHealth Group Inc. ( UNH) and Merck & Co., Inc. ( MRK), all members of the blue chip index, remain within short reach of their 52-week highs, while the DJIA has fallen 5.8% from its own as of Friday afternoon.

  • Motley Fool2 days ago

    What's Behind Johnson & Johnson's Q3 Earnings Success

    Here's why this healthcare giant is out-performing analyst expectations.

  • What $1,000 in Stocks Invested 10 Years Ago Would Be Worth Today
    GoBankingRates2 days ago

    What $1,000 in Stocks Invested 10 Years Ago Would Be Worth Today

    See how Apple stock and other big-name stocks have performed.

  • What’s Pfizer’s Current Valuation?
    Market Realist3 days ago

    What’s Pfizer’s Current Valuation?

    In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).

  • Pfizer’s Dividends and Earnings Quality
    Market Realist3 days ago

    Pfizer’s Dividends and Earnings Quality

    In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.

  • 10 S&P 500 Stocks to Buy for the Long Term
    Kiplinger3 days ago

    10 S&P 500 Stocks to Buy for the Long Term

    The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance

  • Pfizer Reported Revenue Growth in Global Markets
    Market Realist3 days ago

    Pfizer Reported Revenue Growth in Global Markets

    Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.

  • Reuters3 days ago

    Australian watchdog's appeal against Pfizer ruling dismissed by court

    The Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment by a Federal Court in May, when Pfizer was alleged to have abused its market power by offering big discounts and rebates on Lipitor to pharmacies. The drug stores were said to have bought large quantities of the drug and agreed to limit re-supply of competing generic atorvastatin products.

  • Reuters3 days ago

    Australian watchdog's appeal against Pfizer ruling dismissed by court

    Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor. The Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment by a Federal Court in May, when Pfizer was alleged to have abused its market power by offering big discounts and rebates on Lipitor to pharmacies.

  • Motley Fool3 days ago

    Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?

    How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.

  • Investing.com3 days ago

    Intuitive Surgical Earnings miss, Revenue beats In Q3

    Investing.com - Intuitive Surgical (NASDAQ:ISRG) reported third quarter earnings that missed analyst's expectations on Thursday and revenue that topped forecasts.

  • Pfizer’s Growth Rate and Estimates
    Market Realist3 days ago

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

  • Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
    Zacks3 days ago

    Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch

    Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.

  • What Are Pfizer’s Revenue Drivers?
    Market Realist3 days ago

    What Are Pfizer’s Revenue Drivers?

    Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.

  • Novartis Missed Revenue Estimates in Q3 2018
    Market Realist3 days ago

    Novartis Missed Revenue Estimates in Q3 2018

    Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.

  • Pfizer’s Market Cap and Shareholding Pattern
    Market Realist3 days ago

    Pfizer’s Market Cap and Shareholding Pattern

    As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.

  • Analyzing Pfizer’s Stock Performance in October
    Market Realist3 days ago

    Analyzing Pfizer’s Stock Performance in October

    Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.

  • CNBC4 days ago

    Dow stocks Pfizer and UnitedHealth could be safety plays amid market volatility

    In a wild week for the Dow , one corner of the index has proven immune to the worst of the volatility: health care. Dow stocks Pfizer PFE , UnitedHealth UNH and Merck MRK remain within reach of 52-week highs, while the Dow hangs 5 percent from its own.

  • TheStreet.com4 days ago

    Pfizer Confirms to Cut Workforce by 2%

    is looking to cut its total workforce of 90,000 "by a couple percentage points," TheStreet confirmed on Thursday, Oct. 18. The staff cuts "will affect some managerial roles and responsibilities," said company spokeswoman, Sally Beatty, in an email to TheStreet. Earlier, CNBC reported on an internal memo to employees asking workers to retire early to offset the number of people who would need to be laid off.

  • Reuters4 days ago

    Merck, Pfizer combo treatment meets main goals of kidney cancer trial

    The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent. Keytruda is a blockbuster medicine that targets a blockade of proteins known as PD-1 and is approved for a range of other cancers, including lung cancer.

  • Will Pfizer hit $50? Is Cleveland-Cliffs a safe bet ahead...
    CNBC Videos3 days ago

    Will Pfizer hit $50? Is Cleveland-Cliffs a safe bet ahead...

    The "Halftime Report" traders take viewer questions on Pfizer, Mosaic and Cleveland-Cliffs.